Intensity Therapeutics, Inc. (INTS)
INTS moved a median of -0.08% 30 minutes after news, and -0.63% by the close. How INTS actually reacts to news — the realized, point-in-time move the market made, measured across 192 labeled events over the last three years with zero look-ahead.
INTS’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 175 |
| 30-min | -0.08% | 41% | 186 |
| 60-min | -0.17% | 42% | 188 |
| to close | -0.63% | 40% | 191 |
| Middle 50% of INTS reactions | -1.72% to +1.93% |
|---|---|
| Median reaction (30-min) | -0.08% |
| Measured reactions | 192 |
Half of all Intensity Therapeutics, Inc. news events land between -1.72% and +1.93% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when INTS moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to INTS's baseline. Nothing else.
Recent INTS events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | PR Newswire | +0.25% | +0.49% | |
| Form 10-Q INTENSITY THERAPEUTICS, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.00% | +0.72% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Aug 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.72% | |
| Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +0.00% | +0.72% | |
| Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 | Press release | PR Newswire | — | -1.42% | |
| Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) | Press release | PR Newswire | -3.33% | +0.83% | |
| Form S-8 INTENSITY THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | -2.83% | -0.61% | |
| Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 | Press release | PR Newswire | +1.20% | +0.00% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Jun 16 | SEC filing · Form 8-K | SEC EDGAR | — | -1.21% | |
| Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award | Press release | PR Newswire | +2.02% | +4.03% | |
| Form 10-Q INTENSITY THERAPEUTICS, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.52% | -1.55% | |
| Form 8-K INTENSITY THERAPEUTICS, For: May 07 | SEC filing · Form 8-K | SEC EDGAR | -2.52% | -1.55% | |
| Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | PR Newswire | -2.52% | -1.55% | |
| Form ARS INTENSITY THERAPEUTICS, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.29% | -0.38% | |
| Form DEF 14A INTENSITY THERAPEUTICS, For: Apr 30 | SEC filing · Form DEF | SEC EDGAR | +0.29% | -0.38% | |
| Form DEFA14A INTENSITY THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.29% | -0.38% | |
| Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation | Press release | PR Newswire | +0.48% | +1.15% | |
| Form 10-K INTENSITY THERAPEUTICS, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -3.24% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Mar 27 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.24% | |
| Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update | Press release | PR Newswire | +0.00% | -3.24% | |
| Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US | Press release | PR Newswire | +3.76% | +1.20% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +3.76% | +1.20% | |
| Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | Press release | PR Newswire | +2.99% | -3.51% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.58% | |
| Intensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement | Press release | PR Newswire | +0.00% | +2.58% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | +1.05% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Feb 13 | SEC filing · Form 8-K | SEC EDGAR | -2.87% | -5.74% | |
| Intensity Therapeutics Announces Reverse Stock Split | Press release | PR Newswire | -7.14% | -10.64% | |
| Form S-8 INTENSITY THERAPEUTICS, | SEC filing · Form S-8 | SEC EDGAR | -0.76% | -0.20% | |
| Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | Press release | PR Newswire | +0.29% | +2.78% | |
| Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium | Press release | PR Newswire | +0.40% | +2.93% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | +4.89% | +4.08% | |
| Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement | Press release | PR Newswire | +4.89% | +4.08% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Dec 04 | SEC filing · Form 8-K | SEC EDGAR | -2.61% | +4.00% | |
| Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium | Press release | PR Newswire | -2.61% | +4.00% | |
| Form 10-Q INTENSITY THERAPEUTICS, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.02% | -7.12% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +2.02% | -7.12% | |
| Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | PR Newswire | +2.02% | -7.12% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | -3.48% | -10.14% | |
| Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock | Press release | PR Newswire | +5.99% | -26.98% | |
| Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal | Press release | PR Newswire | -4.61% | +71.50% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Oct 22 | SEC filing · Form 8-K | SEC EDGAR | -3.40% | -4.84% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Sep 10 | SEC filing · Form 8-K | SEC EDGAR | +0.76% | -7.04% | |
| Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update | Press release | PR Newswire | -6.38% | -7.21% | |
| Form DEF 14A INTENSITY THERAPEUTICS, For: Sep 09 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -1.46% | |
| Form DEFA14A INTENSITY THERAPEUTICS, | SEC filing · Form DEFA14A | SEC EDGAR | +0.00% | -1.46% | |
| Intensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference | Press release | PR Newswire | +0.32% | -2.17% | |
| Form PRE 14A INTENSITY THERAPEUTICS, For: Aug 28 | SEC filing · Form PRE | SEC EDGAR | -0.35% | -2.08% | |
| Form 8-K INTENSITY THERAPEUTICS, For: Aug 08 | SEC filing · Form 8-K | SEC EDGAR | +0.71% | -6.39% | |
| Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement | Press release | PR Newswire | +1.86% | — |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the INTS section they belong to.
Where else INTS is measured.
INTS earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Intensity Therapeutics, Inc.'s median reaction calculated?
Every labeled INTS news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 192 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of INTS's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does INTS's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.